Join
Live feed
·
INSIDERFilingvia Quantisnow
Prelude Therapeutics Incorporated logo

Chief Chemistry Officer Combs Andrew bought $69,250 worth of shares (100,000 units at $0.69), increasing direct ownership by 26% to 480,123 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
PRLD· Prelude Therapeutics Incorporated
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRLD (Prelude Therapeutics Incorporated) and more on Quantisnow.